Browsing Category
Pharma Industry News
4735 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
VRON-0200’s Spark and Fan model: Is Virion Therapeutics unlocking durable immunity against chronic hepatitis B?
Virion Therapeutics reports sustained immune responses up to one year after a single VRON-0200 dose for chronic HBV. Find out what makes this a potential game-changer.
Nektar Therapeutics (NASDAQ: NKTR) rezpegaldesleukin shows dual action in skin and asthma — is this a pipeline turning point?
Nektar Therapeutics’ rezpegaldesleukin delivers dual efficacy in dermatitis and asthma in Phase 2b REZOLVE-AD trial. See how this Treg-based therapy is changing the game.
New Baxdrostat Phase III data reveal significant ambulatory blood pressure reduction in resistant patients
Find out how AstraZeneca’s Baxdrostat achieved significant blood pressure reductions in resistant hypertension patients in Phase III trials.
AHA 2025: New REDUCE-IT results reveal Vascepa lowers heart attack and stroke risk even when LDL-C is optimal
Find out how AHA 2025 REDUCE-IT results show Vascepa reduces heart attack and stroke risk even when LDL-C is optimal — reshaping cardiovascular prevention.
Why Vir Biotechnology’s tobevibart and elebsiran combo may signal a breakthrough in hepatitis delta treatment
Vir Biotechnology’s hepatitis delta therapy shows 66% RNA clearance at 48 weeks. Find out why this could redefine treatment ahead of 2027 trial results.
Why Innovent Biologics and SanegeneBio believe IBI3016 could change hypertension treatment
Innovent Biologics and SanegeneBio reveal strong Phase 1 data for IBI3016 at AHA 2025. Discover how this RNAi therapy could redefine hypertension treatment.
Ionis Pharmaceuticals’ olezarsen reduces pancreatitis by 85% in late-stage sHTG trial
Ionis Pharmaceuticals reports 85% drop in pancreatitis with olezarsen in Phase 3 sHTG trial. Find out what the AHA late-breaker results could mean for FDA approval.
Is Trellus Health (AIM: TRLS) turning a corner with its new CRO deals, or is dilution still ahead?
Trellus Health signs two CRO contracts and gains preferred vendor status, but runway risk clouds investor sentiment. Find out how markets are reacting.
Merck’s enlicitide slashes LDL-C by 55.8%: Could this daily pill replace PCSK9 injections?
Merck’s enlicitide cuts LDL-C by over 55% in Phase 3 trial. Could it become the first oral PCSK9 inhibitor to transform ASCVD treatment?
Can Alnylam Pharmaceuticals’ vutrisiran reverse cardiac damage? HELIOS-B Phase 3 ATTR-CM trial says yes
New HELIOS-B data shows vutrisiran improves cardiac structure and kidney outcomes in ATTR-CM. Find out how Alnylam’s RNAi drug is reshaping treatment.